40 results about "Hypokalemia" patented technology

A medical monitoring device for monitoring electrical signals from the body of a subject is described. The medical monitoring device monitors electrical signals originating from a cardiac cycle of the subject and associates each cardiac cycle with a time index. The medical monitoring device applies a forward computational procedure to generate a risk score indicative of hyperkalemia, hypokalemia or arrhythmia of the subject. The medical monitoring device can adjust the forward computational procedure based upon clinical data obtained from the subject.

A medical monitoring device for monitoring electrical signals from the body of a subject is described. The medical monitoring device monitors electrical signals originating from a cardiac cycle of the subject and associates each cardiac cycle with a time index. The medical monitoring device applies a forward computational procedure to generate a risk score indicative of hyperkalemia, hypokalemia or arrhythmia of the subject. The medical monitoring device can adjust the forward computational procedure based upon clinical data obtained from the subject.

The present invention relates to a method for reducing infarction comprising administering to a patient ion need thereof a therapeutically effective amount of a composition comprising as an active ingredient a vasopressin antagonist compound and to a composition useful therefor. The present invention also relates to a method for reducing infarction comprising administering to a patient in need thereof a therapeutically effective amount of a combination of a vasopressin antagonist compound and a beta-blocker and to combinations useful therefor. The methods, compositions and combinations of the present invention can be used for reducing infarction in the heart (myocardial infarction) and the brain (stroke). The methods, compositions and combinations of the present invention can also be used for the treatment and / or prevention of hypertension, edema, ascites, heart failure, renal function disorder, vasopressin inappropriate secretion syndrome (SIADH), hepatocirrhosis, hyponatremia, hypokalemia, polycystic kidney disease, diabetes, or circulation disorder.

A medicine in the form of injection, perfusion, tablet, capsule, or oral liquid for preventing and treating hypokalemia, early heartbeat and arrhythmia is prepared from levo-aminosuccinic acid (1-10 wt. portions), potassium salt (1-12) and auxiliary (0-100). Its advantages are sure curative effect, high stability and no pollution.

The invention discloses a potassium magnesium aspartate sterile powder injection and a method for preparing the same. The method is as follows: polyaspartate, magnesium oxide and potassium Hydroxide are prepared into a solution according to a certain method to obtain a liquid medicine, the liquid medicine is subject to reduced-pressure vacuum drying, solvent crystallization or spray drying, and is prepared into sterile packaged products for injection. The potassium magnesium aspartate sterile powder injection of the invention has the advantages of rapid redissolution, excellent stability, simple process, low production cost, suitability for industrial production, etc. the potassium magnesium aspartate sterile powder injection is mainly used for supplementing electrolyte, and can also be used for the treatment of hypokalemia and arrhythmia (mainly ventricular arrhythmia) caused by digitalism, and for the adjuvant treatment of myocarditis sequela, congestive heart failure, and miocardial infarction.

The invention discloses an indapamide sustained-release drug composite and a preparation method thereof. The indapamide sustained-release drug composite comprises the following ingredients: indapamide serving as an active ingredient and a proper amount of filler, framework material, lubricant and copovidone (VA64). The indapamide sustained-release tablet disclosed by the invention is used for treating primary hypertension and is characterized in that the VA64 is added in the prescription so that the burst release of the drug is prevented, the stable release of the drug is guaranteed and the hypokalemia caused by overhigh blood concentration is avoided; in the process, the indapamide is micronized to below 50 micrometers so that the release of the drug is improved and the delayed release of the drug is avoided; and the direct powder compression process is adopted so that the problems that the framework material coheres to form sticky balls due to adhesive and the homogeneity of drug releasing rate is influenced are avoided. The prepared indapamide sustained-release tablet has the advantages that the drug releasing rate is stable; the homogeneity of the releasing rate is good; the drug bioavailability is increased; and the drug quality is guaranteed.

A method for the treatment of depleted intracellular and serum magnesium levels by administration of a highly bioavailable magnesium salt is disclosed. A prescription dispensing system is also disclosed. The highly bioavailable magnesium salt can be administered alone or as adjunctive therapy in conjunction with various medications that cause or exacerbate depleted intracellular magnesium levels, such as renal magnesium wasting medications, including diuretics, immunosuppressants, chemotherapeutic agents, and antibiotics. The highly bioavailable magnesium salt can also be used as adjunctive therapy in conjunction with Class III anti-arrhythmic drugs to attenuate the QTc interval and reduce the risk of fatal arrhythmias, which are a common risk associated with Class III anti-arrhythmic drugs. The administration of a highly bioavailable magnesium salt in accordance with the present invention also serves to restore intracellular potassium levels to normal ranges in patients who remain hypokalemic despite potassium therapy.

A medical monitoring device for monitoring electrical signals from the body of a subject is described. The medical monitoring device monitors electrical signals originating from a cardiac cycle of the subject and associates each cardiac cycle with a time index. The medical monitoring device applies a forward computational procedure to generate a risk score indicative of hyperkalemia, hypokalemia or arrhythmia of the subject. The medical monitoring device can adjust the forward computational procedure based upon clinical data obtained from the subject.

The invention relates to the field of pharmacy and especially relates to a preparation method of a compound sodium chloride-potassium chloride infusion solution. The invention aims at providing a preparation method of an electrolyte supplement and the electrolyte supplement is the compound sodium chloride-potassium chloride infusion solution containing active components of sodium chloride and potassium chloride. Based on a prescribed dose, each 100ml of the compound sodium chloride-potassium chloride infusion solution contains 0.05 to 0.33g of potassium chloride and 0.7 to 1.1g of sodium chloride. The compound sodium chloride-potassium chloride infusion solution is applied by intravenous injection and is suitable for patients having severe hypokalemia or patients unable to take oral medicines. A potassium supplement dose, potassium concentration and a potassium supplement speed of the compound sodium chloride-potassium chloride infusion solution can be set according to clinical conditions, serum potassium concentration and improvement of a potassium deficiency graph of an electrocardiogram.

The invention discloses healthcare soybean milk with a kalium supplementing effect, which is prepared from the following raw materials in parts by weight: 80-90 parts of rice, 60-70 parts of kidney beans, 1-2 parts of cumin, 1-3 parts of roughhaired holly root, 1-2 parts of radix paeoniae alba, 2-3 parts of fructus amomi, 1-2 parts of radix glycyrrhizae, 20-30 parts of yogurt, 15-20 parts of soft white sugar, 15-20 parts of pulp of cornus, 8-12 parts of roses, 20-25 parts of lotus seeds, 22-24 parts of balsam pears, 20-30 parts of avocado, 1-2 parts of a soybean milk additive and a proper amount of water. The soybean milk disclosed by the invention adopts the rice and the kidney beans as the main raw materials, the kidney bean is a scarce food with high kalium and magnesium content and low sodium content, has functions of improving immunocompetence of human blood bodies, enhancing disease resistance, activating lymph T cells, boosting the synthesis of deoxyribonucleic acid, meanwhile has an effect on resisting the development of tumor cells, and can ameliorate patients suffering from heart disease, arteriosclerosis, hyperlipidemia, hypokalemia, salt contraindication and the like. In addition, the added avocado is rich in various vitamins, various mineral elements, edible plant fibers, and fat with 80 percent of unsaturated fatty acid, is a high-energy and low-sugar fruit, and has important physiological functions of lowering cholesterol and blood lipid, protecting heart vessels, eyes and liver system and the like.

The invention relates to the field of processing of special medicinal formula food, and specifically discloses an ERAS energy beverage. The ERAS energy beverage is prepared from the following raw materials: maltodextrin, fructo-oligosaccharide, vitamin B1, vitamin B6, vitamin B12, potassium chloride, zinc gluconate, sodium citrate, citric acid, malic acid, taurine and water. Compared with the prior art, the ERAS energy beverage provided by the invention provides sufficient nutrients and energy for a human body, provides energy intake for patients before an operation, relieves thirst and anxious emotion, and decreases the incidence rate of preoperative hypokalemia and the severity of hypokalemia. Meanwhile, the energy beverage provided by the invention is stable and has stable and proper viscosity and good mouthfeel.

The present invention is with oyster shuck powder as carrier to prepare potassium chloride stomach retention floating type slow release tablet, belonging to pharmaceutical preparation technique field. The technique is characterized in that its main components are oyster shuck powder and potassium chloride. The tablet can retain in stomach and prolong the medicine releasing time, improve the medicine absorption, be beneficial to promote bioavialability. The preparing technique process of the present invention is simple, convenient and reasonable operation, suitable for industrial production. And the price is achievement, using convenient, beneficial to large scale spreading and application. The medicine has calcium-replenishing function while treating hypokalemia, and relieved toxic effect of potassium ion to heart. The present invention has little dosage, good effect, and good market prospect.

The disclosed invention includes: a device and method of performing physiological sweat sensing device calibration; a device and method of indicating an individual's dehydration state; a device and method of indicating an individual's stage in their ovulation cycle; a device and method of indicating that an individual is hypokalemic or hyperkalemic; a device and method of indicating that an individual is entering a hypoglycemic state; a device and method of indicating an individual's glucose trend value; and a device and method of indicating that an individual has experienced toxic substance exposure.

The invention discloses an indapamide sustained-release drug composite and a preparation method thereof. The indapamide sustained-release drug composite comprises the following ingredients: indapamide serving as an active ingredient and a proper amount of filler, framework material, lubricant and copovidone (VA64). The indapamide sustained-release tablet disclosed by the invention is used for treating primary hypertension and is characterized in that the VA64 is added in the prescription so that the burst release of the drug is prevented, the stable release of the drug is guaranteed and the hypokalemia caused by overhigh blood concentration is avoided; in the process, the indapamide is micronized to below 50 micrometers so that the release of the drug is improved and the delayed release of the drug is avoided; and the direct powder compression process is adopted so that the problems that the framework material coheres to form sticky balls due to adhesive and the homogeneity of drug releasing rate is influenced are avoided. The prepared indapamide sustained-release tablet has the advantages that the drug releasing rate is stable; the homogeneity of the releasing rate is good; the drug bioavailability is increased; and the drug quality is guaranteed.

An application of scutellaria baicalensis in preparing a medicament for treating ascites due to cirrhosis relates to a novel application of the scutellaria baicalensis. The invention aims at providing a novel application of the scutellaria baicalensis, and particularly relates to the application of the scutellaria baicalensis in a medicament for treating ascites due to cirrhosis, a medicament for treating liver function damage, a medicament for treating hepatic fibrosis, a medicament for treating liver tissue damage, a medicament for treating hypoproteinemia and a medicament or treating cholestasis. Compared with a modern therapy method, the application of the scutellaria baicalensis has the advantage that the complications, such as hepatic encephalopathy, renal function damage, hyponatremia, hypokalemia or hyperkalemia and the like are avoided, also has the advantages of low treatment cost, simple use method, ideal treatment effect and the like and is conductive to clinical practical application. The scutellaria baicalensis is used for treating ascites due to cirrhosis.

The electrolyte replenishing agent for treating hypokalemia and hypomagnesemia includes the medicine with magnesium aspartate hydrochloride and potassium aspartate in the weight ratio of 1 to 0.1-10 as active components. The electrolyte replenishing agent can replenish body with potassium and magnesium ions, maintain the intracellular non-dissociation acid-base metabolism balance and raise the bioavailability of potassium and magnesium ions in body.

The invention discloses a peach wine making process. The peach wine making process comprises the following steps that a, peaches with moderate individual sizes are selected and washed clean, and pitsare removed; b, the peaches are pressed into jam; c, the jam and white granulated sugar which is 5% by weight relative to the jam are mixed and decocted, a decoction temperature is 60 DEG C-70 DEG C,the decoction time is 1 h, and decoction liquid is obtained; and d, the decoction liquid is mixed with a yeast which is 0.05% by weight relative to the decoction liquid and sealed at 18 DEG C-23 DEG Cfor fermentation for 30-35 days to obtain the peach wine. The moderate drinking of the peach wine can promote blood circulation and benefit qi; and the peaches are rich in crude fiber, potassium, iron and calcium, and long-term moderate drinking of the peach wine can improve hypokalemia and iron-deficiency anemia.

The invention discloses a stomach cleaning combined reagent used for the gastroenterology department. The stomach cleaning combined reagent comprises the following ingredients in parts by weight: 10-20 parts of panax notoginseng, 3-9 parts of radix astragali, 5-15 parts of radix codonopsis, 10-15 parts of Mangnolia officinalis, 8-12 parts of radix glycyrrhizae, 5-15 parts of rhizoma corydalis, 12-20 parts of cistanche salsa, 10-15 parts of bitter gourds, 3-8 parts of honeysuckles, 5-10 parts of endothelium corneum gigeriae galli, 8-10 parts of chrysanthemums, 5-10 parts of fructus forsythia, 3-7 parts of royal jelly, 2-8 parts of honey, 5-10 parts of rhizoma cyperi, 5-15 parts of fresh ginger, 10-15 parts of barleys, 50-100 parts of normal saline and 50-100 parts of 10% potassium chloride.Compared with the prior art, the stomach cleaning combined reagent has the beneficial effects that the incidence rate of complications, that is the incidence rate of hyponatremia and hypokalemia in astomach cleaning process can be reduced; meanwhile, the stomach cleaning combined reagent has an effect of nursing a stomach and is beneficial to later recovery of the stomach.

The invention relates to the technical field of medicines, and in particular relates to a traditional Chinese medicine for treating hyperuricemia complicated with joint swelling. The traditional Chinese medicine is prepared from the following medicinal materials in parts by weight: 20-30 parts of folium isatidis, 20-30 parts of dandelion, 20-30 parts of notopterygium root, 15-25 parts of herba potentillae discoloris cum radice, 15-25 parts of cortex moutan, 13-17 parts of rhizoma anemarrhenae, 13-17 parts of herba centellae, 10-20 parts of indigo naturalis, 10-20 parts of herba houttuyniae, 10-20 parts of fructus trichosanthis, 15-19 parts of radix paeoniae rubra, 12-18 parts of rhizoma atractylodis, 11-17 parts of rhizoma coptidis, 10-14 parts of rhizoma smilacis glabrae, 10-14 parts of rhizoma polygoni cuspidati, 10-14 parts of radix notoginseng, 10-14 parts of black soya beans, 11-17 parts of rhizoma cyperi, 10-18 parts of radix saposhnikoviae, 10-22 parts of herba artemisiae annuae, 5-9 parts of herba plantaginis, and 3-7 parts of licorice root. For the traditional Chinese medicine for treating hyperuricemia complicated with joint swelling, through scientific mixing, the ingredients achieve a synergic effect, so that the traditional Chinese medicine can promote the discharge of uric acid, supplement the elements including sodium, potassium, calcium, zinc and the like, and prevent the side reactions including hyponatremia, hypokalemia, hypocalcemia and the like, and also has the efficacies of relieving swelling and pain, regulating Qi and blood, clearing damp and dissolving turbidity, and treating arthritis.

The invention belongs to the technical field of medical treatment, and discloses a lavage fluid as well as a preparation method and application thereof, and the lavage fluid comprises the following components: normal saline, buffer alkali, potassium chloride, a sodium channel blocker and furosemide. The inventor carries out a large number of experiments in the earlier stage and accidentally finds that according to the technical scheme, due to the reasonable proportion and the combination of all the components, water-salt electrolyte and acid-base balance disorder of an organism caused by the fact that lavage fluid is absorbed or directly enters a circulating system can be effectively relieved or avoided, such as high chlorine acidosis, hypokalemia, high blood volume, decrease of oxygenation index and the like; therefore, the blood dilution is effectively avoided, postoperative BNP and troponin I (cTnI) levels are reduced, the anterior load of the heart and myocardial injury are relieved, pulmonary interstitial edema is relieved, the exchange function of the lung is protected, operation related complications are reduced, and postoperative rehabilitation of a patient is facilitated. The lavage fluid disclosed by the invention is widely applied to the surgical operation of continuous surgical field lavage, has a wide application prospect and is worthy of being vigorously popularized.

The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.

A method for the treatment of depleted intracellular and serum magnesium levels by administration of a highly bioavailable magnesium salt is disclosed. A prescription dispensing system is also disclosed. The highly bioavailable magnesium salt can be administered alone or as adjunctive therapy in conjunction with various medications that cause or exacerbate depleted intracellular magnesium levels, such as renal magnesium wasting medications, including diuretics, immunosuppressants, chemotherapeutic agents, and antibiotics. The highly bioavailable magnesium salt can also be used as adjunctive therapy in conjunction with Class III anti-arrhythmic drugs to attenuate the QTc interval and reduce the risk of fatal arrhythmias, which are a common risk associated with Class III anti-arrhythmic drugs. The administration of a highly bioavailable magnesium salt also serves to restore intracellular potassium levels to normal ranges in patients who remain hypokalemic despite potassium therapy.

The invention disclosed a method for promoting fast recovery from abdominal surgery by the aid of a hypokalemia preventing and controlling system. The method includes three steps: (1) monitoring serum kalium; (2) intervening pathogenesis; and (3) handling hypokalemia. The method is simple in process steps and convenient in operation, the hypokalemia preventing and controlling system is more necessarily built for a patient before the patient is hospitalized, accordingly, conditions for early prevention, early discovery, early correction, early surgery and early recovery for the hypokalemia patient in open surgery are created, furthermore, limited bed resources during a surgery waiting period can be saved for inpatient areas, and the method also can provide beneficial experiences for other specialized fields. The method has integrated functions of medical treatment, nursing, prevention and education, and shows a perfect mode for realizing combination intervening for patients in and out of hospitals.

The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.

The invention discloses a preparation method and process of veterinary medicine of diarrhea relieving powder. The diarrhea relieving powder concretely comprises the following ingredients in parts by weight: 15 to 20 parts of radix puerariae, 35 to 45 parts of rhizoma coptidis, 15 to 20 parts of radix scutellariae, 10 to 15 parts of liquorice roots, 10 to 15 parts of honeysuckle flowers, 5 to 15 parts of common andrographis herb, 5 to 10 parts of a gastrointestinal function recovering agent, 25 to 30 parts of a feed additive, 10 to 15 parts of a nutrition recovering agent, 10 to 15 parts of cyclodextrin and 10 to 15 parts of a suspending agent. The preparation method and process of veterinary medicine of diarrhea relieving powder has the advantages that all of hawthorn fruits, medicated leaven, fructus hordei germinates and endothelium corneum gigeriae galli have the efficacies of strengthening the spleen, harmonizing the stomach, promoting digestion to relieve retention and resolving turbidity to reduce lipid; after sick cattle take the diarrhea relieving powder, the symptoms can be relieved, and the gastrointestinal functions of the sick cattle can be favorably and fast recovered;the fast health recovery of the sick cattle is facilitated; through the addition of an acidifying agent, calcium formate and glucose powder, inorganic salt ions and energy lost by the sick cattle dueto diarrhea can be supplemented, the balance of the inorganic salt metabolism is maintained; the sick cattle are helped to fast recover the nutrition; and the occurrence of hyponatremia or hypokalemia is prevented.

The present invention is with oyster shuck powder as carrier to prepare potassium chloride stomach retention floating type slow release tablet, belonging to pharmaceutical preparation technique field. The technique is characterized in that its main components are oyster shuck powder and potassium chloride. The tablet can retain in stomach and prolong the medicine releasing time, improve the medicine absorption, be beneficial to promote bioavialability. The preparing technique process of the present invention is simple, convenient and reasonable operation, suitable for industrial production. And the price is achievement, using convenient, beneficial to large scale spreading and application. The medicine has calcium-replenishing function while treating hypokalemia, and relieved toxic effectof potassium ion to heart. The present invention has little dosage, good effect, and good market prospect.

The invention provides a postpartum nutritional supplement for dairy cows, and belongs to the technical field of livestock feed. The supplement is prepared from the following raw materials: glucose, potassium chloride, sodium bicarbonate, magnesium sulfate, benzyl acetate, calcium lactate, an antioxidant, wine brewing yeast, zinc sulfate, calcium iodate, sodium selenite, cobaltous sulfate, vitamin A, vitamin pp, vitamin D3 and vitamin E. The nutritional supplement for the postpartum dairy cow is used for improving the growth performance of the postpartum dairy cow and can supplement electrolyte for the growth of the postpartum dairy cow and promote metabolism, so that hypocalcemia and hypokalemia are prevented, postpartum uterine contraction is increased, fetal membranes are promoted to be discharged, and finally the risks of milk fever, retained fetal membranes, hysteritis and the like of the dairy cow are reduced.

The invention provides a method for preparing orally disintegrating tablets for treating hypokalemia by 3D printing. The method includes: well mixing medicinal potassium chloride raw powder and auxiliary materials, and adopting mixed solution of ethanol water, glycerin, polysorbate 80 and Plasdone-k29 / 32 (or Plasdone-K30) to prepare tablets by powder-liquid 3D printing. The tablets prepared according to the method are great in taste, easy to disintegrate, high in hardness, portable and simple in preparation process, and the foundation is laid for individual accurate medication.